Showing 1 - 3 of 3 ondo or waln or ashizawa
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) (REGENERATE-PD)

Status: Enrolling

Investigator: William Ondo

Study Coordinator: Daniel Arnaud Dominguez

Phone: 346.356.3635

The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease. ... Read more >

COVID-19 on the brain

Status: Enrolling

Investigator: Tetsuo Ashizawa

Study Coordinator: Valerie Flores

Phone: 713.363.9803

While solid evidence for direct CNS infection by SARS-CoV-2 is lacking, a consensus has been forming that affected patients are at higher risk of developing neuropsychiatric and neurologic sequelae after overcoming the primary infection, as a co ... Read more >

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

Status: Enrolling

Investigator: William Ondo

Study Coordinator: Daniel Arnaud Dominguez

Phone: 346.356.3635

This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 ... Read more >